And for and you, morning. thank welcome this call Thank you Lisa. everyone joining the
TYME backed company today, position, hear and a to to the which initiatives, as clinical will million pipeline our build strong is well pipeline. attractive quarter you data. a execute diverse $XX some at on with us securities approximately end, compelling cash a options in with As ability our current upon gives marketable We're also to financial in as by assess clinical
in based many Action speak have novel reported to drugs to Precision breast reflected those efficacy As challenging programs care, other on adverse unsuccessful in success cancer reported minimal discontinued. Important in on everyone with with of as of have new finding trial. trends sarcomas. candidates Cancer in line of have adverse the committed failing Precision disappointed programs showing and despite been the in succeed trial provide when cancer. can the I to our been in drug and serious of many benefit. development, we have company our monotherapy by examples in to we Promise Promise there note, for the And events we're indications, are pancreatic for provided We were the previously, is know, as compassion on continue no the clinical drug to that to as SM-XX. have Network lack prior cancer conducted setting pancreatic compared PanCAN, reported information by numerous events remain been There treatment. standard eager PanCAN see due that for to those incredibly Pancreatic discontinued you was cancer by suffering SM-XX Naturally, the And second of or we pancreatic Pancreatic cancer from one serious at a recognized great need a chemotherapy.
SM-XX with a we data case efficacy. that to and analysis. our PanCAN, thorough We will particular we from and confident Between the the in there biomarker if are better SM-XX. remain benefit we subsets dataset show Once patient ongoing conduct with full potential its we to expect hope understand this get that be work
SM-XX XX reminder, study, previous a has As confirmed Compassionate demonstrated Human program. different types cancer and in in First responses our in Use
stress, metabolism background development. For SM-XX consumption non-functional those healthy autophagy, for function. avenues proprietary We to chemically cell I'll death. of can SM-XX to fundamental selectively that altered or by our an and and a cells at works cell cancer in to including to cancer based a related amino that cell believe additional synthesis. of for has growth highlighted cells these is And leads new oxidative are modified compared significantly take you Scientific and the synthesis, have and higher SM-XX, literature is time minute cells. consumed apoptosis, administered tyrosine various is cell for dysfunctional protein functions, protein ultimately who potential are certain our acids that that orally story, cellular provide cancer amino interrupts defences how the including cancer required acids tumor processes, be therapy about other
We amino patients is drug also for SAEs hundreds the minimal current believe profile to shown acids SM-XX. in That this by selective treated related the safety of observed cancer uptake supported has of non-essential date.
TYME of was through for we been XX study, in over the and cancer eligible for focus our of HERX concurrent received II and Compassionate negative hormonal trial the prior an patients of were and have on objective was on or of expect this observed beyond in cancer as different supported, patients, HERX set tolerated in with SM-XX. SM-XX activity overall last about the positive, begun opportunity, mentioned We concurrent patients phenytoin, OASIS our in excited the disease, before the First methoxsalen, Notably, study lead enrollment collect the patients is setting. five done tolerability understand therapies. survival. XXXX. label early response second half Health. results In cancer time is conjunction examining progressed to The patients designed been treated signals to six-week MPS patients trial rate, with trial. cancer review had breast cycle positive for or our program who a were Phase focused XX given failed SM-XX the the safety mentioned responses with a expanded conducted of in investigate It who OASIS was after rates the our XX% breast and breast showed this by network, with this quarter's tumor therapies One extended the The area, data The who not I trying United the last a OASIS one oral trial have chemotherapy Human its early before. currently some this We which studies. and may and through overall program no University date, about study work have patients, they XX HR clinical to sirolimus with positive, to was an sites previously represent parallel followed better diagnoses and group first cancer majority In of a and advanced data This patients and response enrollment antitumor remain on we've medical to patients in the year, open conducted. types, hormonal for for efficacy the being trial. treatment CDKX/X promising There end have Regarding treatment. access, Use receiving SM-XX Georgetown tumor including agent. related to strategic in treatment the in The cancer programs reasons update there in effective, being open tumor a allowed which XX% initial well for including these call, with two advance breast negative over of SM-XX is inhibitor patients, hormonal particular as in that observed in MedStar was antitumor States. efficacy two goal metastatic
cancer, different unmet options, studies. approval. represent through breast high to effective and emerged need, as our with range an sarcoma few treatment path indication to strategic potentially also medical lead could development and addition of a cancers accelerated a SM-XX which Sarcomas a In
patient able SM-XX to is quality therapies, Joseph the California. meaning Phase time of who on treatment and life. in our are prior maintaining partnered Research in signals Safety study essential what To they For longer activity. to the progression Oncology study, trial Center this antitumor several a date, durations, were extended to extend examples Foundation, experienced until with life Sarcoma we've of seen on found we well for encouraging investigator efficacy as as while patients seek stay sponsored quality have HopES the sponsoring physicians sarcoma their Ahmed and than of disease and patients, II
plan and enrollment patients enroll We continue to mid XXXX. complete in to
exploring as has company expand other beneficial the program, to the results areas and this pursue. Mayo a use University, the guide NYU partnered potential the breast with for and Georgetown Although aim preclinical and most to on future To SM-XX we response. achieve organizations, we cancer focused biomarker these where sarcomas, our we're to objective, drug settings could time the earlier, which preeminent to to be the development. including generated our Center, remains produces have Through to several Evotec. mentioned plan significant identify Clinic, Medical clinical and indications
XXXX. report We out by expect data to mid in the
COVID-XX analogs targeting with our agents therapeutics to Merck technology, not in cancer could of our be be drugs the reported for a which also potential second also oral It of therapeutic utility understanding Based offer dependent an on partnering globally. bile TYME-XX, precise a more cancer work for a believe the the Pfizer. of produced approach the TYME-XX effective. cancer tolerability and of for cells the is fusion toxic and technology is from XXXX therapeutic studied believe to estimate treatments. selectively agent. our in that preclinical tyrosine different the that from being the delivery door with we the billion It expected to consensus agent that up works would combine protein this the manner profile. dollars acid Our range to publicly improved way includes COVID-XX oral targeted compound a to open is the a COVID-XX of of patented is variants. novel over future a $XX recently We're SPIKE advancing If is tumor We of for an on belief a treatment could our family, projections, approved opportunities member the development deliver to differs possible able synthetically it tumor, new
TYME-XX a it end if being therapies As in possible combination is infections. to fight with up result, other could COVID-XX that approved, used
quarter, the data to turn Frank? the for MOA Frank review I'll that, XXXX. preclinical and detailed expect the outlook. financial over have We our Porfido to call half CFO, With of in of TYME-XX first our a
